• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

FDA Approves Babesia microti Screen for Plasma and Whole Blood Donations

March 14, 2018

One to two thousands cases of babesiosis are reported in the United States (U.S.) each year, mainly in the Northeast and upper Midwest. Babesiosis infections are normally asymptomatic, but can cause flu-like symptoms that may become life-threatening, especially in individuals with weakened immune systems. The tick-born pathogen Babesia microti is responsible for the majority of cases, but the hemolytic parasite is also the most common transfusion-transmitted parasitic infection in the U.S. Previously there were no U.S. Food and Drug Administration (FDA) approved assays for babesiosis. Investigational use of arrayed fluorescence immunoassays and real-time PCR for detecting B. microti antibodies in plasma and nucleic acid in whole blood samples, respectively, have removed hundreds of B. microti-infected blood donations since 2012 and have demonstrated the effectiveness of the new screening tools. The FDA just approved these two B. microti screening tests. Guidelines for their use are expected later this year.

Reference:

FDA News Release. FDA approves first tests to screen for tickborne parasite in whole blood and plasma to protect the U.S. blood supply, March 6, 2018.

 

Filed Under

  • News
  • Transfusion Transmitted Infections

Recommended

  • Fresh Red Blood Cell Transfusions Do Not Improve Outcomes in Critically Ill Patients

  • Aryl Hydrocarbon Receptor Plays Important Role in Red Cell Development

  • Whole Blood Transfusions on the Battlefield

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Plasma Equivalent to Clotting Factor Concentrates for Initial Resuscitation of Patients with Severe Trauma

  • Personalized Prediction Model of Prophylactic Platelet Transfusions for Preterm Infants

  • Caffeine in Donor Blood Reduces Quality of Stored RBCs

  • Ferritin Levels Needed to Assess Hemoglobin Recovery after Blood Donation

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley